

SeqOne Accelerates Growth and Expansion into Multi-Omics with Life & Soft Acquisition

Strategic acquisition bolsters SeqOne's multi-omics capabilities and expands service offerings with ISO-certified sequencing platform

MONTPELLIER, FRANCE — April 7, 2025 — SeqOne, a leader in AI-powered genomic analysis solutions, today announced the acquisition of Life & Soft, a Paris-based specialist in multi-omics data analysis and bioinformatics services. This strategic move strengthens SeqOne's position as a European leader in genomic bioinformatics and accelerates its global expansion strategy.

"This acquisition represents a pivotal moment in SeqOne's growth trajectory," said Martin Dubuc, Chief Executive Officer of SeqOne. "By integrating Life & Soft's complementary expertise in multi-omics and bioinformatics services, we're not only expanding our technological capabilities but also accelerating our mission to democratize precision medicine globally. Together, we're creating a more comprehensive solution for molecular laboratories worldwide."

The acquisition comes during a period of exceptional growth for SeqOne, which has:

- Expanded its international presence from 3 to over 20 countries in just 12 months
- Doubled its customer base to 140 active molecular laboratories
- Positioned itself to support more than 100,000 genomic tests annually

Life & Soft brings valuable assets to the SeqOne portfolio, including proprietary software for analyzing complex genomic, metagenomic, and virological data, advanced tools for monitoring and managing NGS platform operations, an ISO 9001-certified sequencing platform within the prestigious CEA (French Alternative Energies and Atomic Energy Commission), and established relationships with major clients from CAC 40.

Life & Soft will operate as a wholly owned subsidiary of SeqOne, maintaining its distinctive expertise while benefiting from SeqOne's robust infrastructure and global reach. The integration creates a uniquely positioned entity offering both sophisticated software solutions and flexible services—from à la carte options to complete end-to-end drylab workflows—enabling laboratories of all sizes to access cutting-edge genomic technologies.

"This acquisition perfectly aligns with our vision to make personalized medicine accessible to all patients, everywhere," added Dubuc. "By combining our strengths, we're creating

an unparalleled platform that will empower more laboratories to deliver precision care at scale."

About SeqOne

SeqOne is a leading European provider of AI-powered software for next-generation sequencing (NGS) data analysis in oncology and rare diseases. Its cloud-based platform transforms complex genomic data into fast, precise, and actionable insights, supporting molecular labs in delivering life-saving diagnoses and treatments. The SeqOne Platform is CE-IVD Class C certified under IVDR as an in vitro diagnostic medical device. Driven by the vision of personalized medicine for every patient, everywhere, SeqOne is scaling the future of genomic medicine—one lab at a time.

For more information, visit www.seqone.com

Media Contact:

Madeleine Latapie
VP, Marketing & Communications
madeleine.latapie@seqone.com